Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Growth Is Reshaping Competitive Advantage Across The Industry
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Size Forecast: How Large Could The Market Become By 2030?
The size of the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market has experienced swift expansion over the last few years. This market is expected to increase from $1.06 billion in 2025 to $1.22 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.6%. Historically, this expansion has been driven by factors such as wider coverage of cervical cancer screening programs, the integration of molecular diagnostics into gynecology, heightened awareness regarding the risks associated with hr-hpv infection, the widespread availability of automated PCR platforms, and the proliferation of centralized diagnostic laboratories.
The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market is anticipated to experience substantial growth in the coming years, with its size expected to reach $2.12 billion by 2030, growing at a compound annual growth rate (CAGR) of 14.9%. This projected expansion during the forecast period is driven by several factors, including an increasing shift towards primary HPV screening, a growing need for high-specificity cancer risk stratification, the expansion of population-based screening initiatives, the integration of digital pathology and reporting systems, and rising investments in precision diagnostics. Key trends expected over this period include the increased adoption of mRNA-based primary cervical screening assays, the growing utilization of fully automated molecular testing platforms, the rising integration of genotype-specific reflex testing, the expansion of high-specificity screening algorithms, and an enhanced focus on clinically actionable HPV detection.
Download A Free Sample Report For Comprehensive Market Insights:
Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Opportunity Drivers: What Is Creating New Revenue Potential?
The escalating occurrence of cervical cancer is anticipated to fuel the expansion of the cervical human papillomavirus messenger ribonucleic acid testing market moving forward. Cervical cancer, a malignant condition originating in the cervix cells, is primarily caused by persistent infections with high-risk human papillomavirus types and represents a significant contributor to cancer-related illness and fatalities among women globally. The rising incidence of cervical cancer is attributed to low participation in cervical screening programs, which delays detection and allows persistent human papillomavirus infections to progress into cancer. Cervical human papillomavirus messenger ribonucleic acid testing facilitates the identification of active high-risk human papillomavirus infections, which is crucial amidst the increasing prevalence of cervical cancer, thus improving risk assessment and enabling timely interventions to slow down cervical cancer progression. For instance, in December 2025, as reported by Cancer Australia, an Australia-based Government Agency, there were 265 deaths from cervical cancer in Australia in 2023, with an estimated 254 deaths from cervical cancer in 2025. Therefore, the growing prevalence of cervical cancer is a primary catalyst for the growth of the cervical human papillomavirus messenger ribonucleic acid testing market.
Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Segments: Where Are The Largest Growth Opportunities?
The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market covered in this report is segmented –
1) By Product Type: Assay Kits; Instruments; Reagents And Consumables
2) By Application: Cervical Cancer Screening; Research; Other Applications
3) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutes; Other End Users
Subsegments:
1) By Assay Kits: Messenger Ribonucleic Acid Detection Kits; Multiplex Testing Kits; High Risk Genotype Specific Kits; Screening And Diagnostic Kits
2) By Instruments: Real Time Polymerase Chain Reaction Systems; Automated Molecular Analyzers; Sample Preparation Systems; Nucleic Acid Extraction Instruments
3) By Reagents And Consumables: Primers And Probes; Enzymes And Buffers; Controls And Standards; Extraction And Purification Consumables
Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Innovation Trends Driving Future Development
Companies operating within the cervical human papillomavirus messenger ribonucleic acid (mRNA) testing market are prioritizing the development of technological advancements, notably multiplex real-time PCR innovations. This strategic focus aims to secure a competitive advantage by enhancing diagnostic accuracy, facilitating simultaneous E6/E7 mRNA detection and high-risk HPV genotyping, reducing false positives, lowering testing costs, and expanding adoption. Multiplex real-time PCR innovations specifically enable the simultaneous detection and quantification of multiple HPV E6/E7 mRNA targets and high-risk genotypes in a single PCR reaction, thereby improving the accuracy, efficiency, and clinical relevance of cervical HPV testing. For example, in July 2024, Medicon Hellas S.A., a Greece-based diagnostics company, introduced a multiplex real-time PCR kit for HPV E6/E7 mRNA genotyping, acting as the exclusive distributor for Uni-Medica in Greece and Cyprus. This kit boasts compatibility with various PCR instruments, including Bio-Rad CFX96 and Hongshi SLAN-96 series, for fluorochrome analysis with ct values, and is applicable to diverse samples such as semen, urine, and anal swabs, extending beyond cytology. Furthermore, it carries CE-IVD marking and delivers results within 2.5 hours.
Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Major Participants And Competitive Dynamics
Major companies operating in the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Eurofins Scientific, Agilent Technologies Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Co-Dx Ltd., Promega Corporation, Seegene Inc., Molbio Diagnostics, QIAGEN N.V., Sansure Biotech Inc., Xiamen Zeesan Biotech Co. Ltd., DiaCarta Inc., Operon S.A., AB ANALITICA s.r.l., Arbor Vita Corporation, Mylab Discovery Solutions, Guangdong Hybribio Biotech Co. Ltd., Atila Biosystems, GeneFirst Ltd., Advanced Molecular Diagnostics.
Access The Complete Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Report:
Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the cervical human papillomavirus (HPV) messenger ribonucleic acid (mRNA) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model